In KEYNOTE-054 Part 2, PFS and ORR after recurrence and crossover to pembrolizumab were similar to previous studies of immune checkpoint therapy for advanced melanoma, but pembrolizumab rechallenge had minimal activity.
Neoadjuvant relatlimab plus nivolumab produced high rates of pCR and MPR in patients with resectable stage III melanoma with a tolerable safety profile.
Dual LAG-3 and PD-1 inhibition with a fixed-dose combination of relatlimab + nivolumab demonstrated superior PFS compared with nivolumab alone in patients with advanced melanoma.
Updated data from the LEAP 004 trial of lenvatinib plus pembrolizumab in patients with advanced melanoma and confirmed progression on anti–PD-1/PD-L1 therapy resulted in durable responses and no new safety signals.
Updated data continue to show encouraging safety and efficacy of TIL therapy with lifileucel in advanced/metastatic melanoma after progression on prior anti–PD-1/PD-L1 and BRAF ± MEK inhibitors.
CheckMate 067 6.5-year follow-up finds a median overall survival of 72.1 months with nivolumab + ipilimumab in patients with advanced melanoma, durable benefits across subgroups, and no new safety signals.
In the 5-year follow-up of the COLUMBUS trial, encorafenib plus binimetinib continues to show a survival benefit in patients with BRAF V600–mutant melanoma with no new safety signals.
An update of the ABC study at 5 years shows that nivolumab plus ipilimumab has enduring activity in patients with asymptomatic melanoma brain metastases.
Three-year follow-up of CheckMate 511 shows continued improved safety and comparable efficacy of NIVO3 + IPI1 vs NIVO1 + IPI3 for patients with advanced melanoma.